Research and Markets has announced the addition of the " Belgium Pharmaceutical Market Analysis, 2010-2014 :
The Belgium pharmaceuticals market generated total revenues of $6,415.8 million in 2009, representing a compound annual growth rate (CAGR) of 5.6% for the period spanning 2005-2009. In comparison, the French and German markets grew with CAGRs of 3.2% and 3.1% respectively, over the same period, to reach respective values of $37,306.2 million and $37,139.2 million in 2009.
Cardiovascular sales proved the most lucrative for the Belgian pharmaceuticals market in 2009, gene-rating total revenues of $1,412.9 million, equivalent to 22% of the market's overall value. In comparison, sales of central nervous system generated revenues of $1,010.2 million in 2009, equating to 15.7% of the market's aggregate revenues.
The Belgium pharmaceuticals market generated total revenues of $6,415.8 million in 2009, representing a compound annual growth rate (CAGR) of 5.6% for the period spanning 2005-2009. In comparison, the French and German markets grew with CAGRs of 3.2% and 3.1% respectively, over the same period, to reach respective values of $37,306.2 million and $37,139.2 million in 2009.
Cardiovascular sales proved the most lucrative for the Belgian pharmaceuticals market in 2009, gene-rating total revenues of $1,412.9 million, equivalent to 22% of the market's overall value. In comparison, sales of central nervous system generated revenues of $1,010.2 million in 2009, equating to 15.7% of the market's aggregate revenues.
No comments:
Post a Comment